ヘルパンギーナ治療市場- 世界の産業規模、シェア、動向、機会、予測、治療法別、ウイルス別、エンドユーザー別、地域別、競合別、2020～2030年

ヘルパンギーナ治療の世界市場規模は2024年に18億9,000万米ドル、予測期間には28億6,000万米ドルに達し、2030年までのCAGRは7.14%と予測されます。

ヘルパンギーナ治療の世界市場は、特に小児を中心にウイルス感染症の流行が増加しているため、着実な成長を遂げています。ヘルパンギーナは、コクサッキーウイルスAなどのエンテロウイルスによって引き起こされ、のどの痛みを伴う潰瘍や発熱を引き起こし、鎮痛剤、解熱剤、水分補給療法による対症療法が必要となります。ヘルパンギーナの罹患率の上昇と、ウイルス感染に対する親の意識の高まりが相まって、効果的な治療オプションへの需要が高まっています。ヘルスケアプロバイダーは早期診断と適切な支持療法を重視しており、市場拡大に寄与しています。市販の疼痛緩和薬の入手可能性と小児医療施設の進歩は、罹患者の症状のタイムリーな管理を保証し、市場の成長をさらに後押ししています。

遠隔医療やデジタルヘルスケアソリューションの普及により、小児科受診へのアクセスが大幅に向上し、ヘルパンギーナ症例の迅速な診断と管理が可能になりました。抗ウイルス療法の継続的な研究と標的治療アプローチの開発は、市場に革命をもたらすと期待されています。エンテロウイルス関連感染症のワクチン接種調査を含む予防ヘルスケアへの注目の高まりは、潜在的な成長の道を示しています。製薬会社は小児用製剤に積極的に投資しており、若年患者に合わせた安全で効果的な治療ソリューションを確保しています。ヘルスケア・インフラの拡大と医療費の増加は、特に新興経済圏において、医療サービスへのアクセシビリティを高める原動力となっています。

低開発地域では、ヘルパンギーナの症状や治療法に関する認識が低いことが大きな課題となっています。ヘルパンギーナに対する特定の抗ウイルス薬がないため、対症療法に頼ることになり、治療の進歩が制限されます。自己投薬や疼痛緩和薬の不適切な使用に関する懸念は、さらに効果的な疾患管理を妨げています。小児用医薬品の承認に関する厳しい規制要件が、新規治療法の開発と商業化に複雑さをもたらしています。また、この市場は季節的な感染症流行に関連した課題にも直面しており、需要の変動が生じるため、ヘルスケアシステムが一貫した準備態勢を維持することが難しくなっています。このような課題に対処するためには、医療機関、政府、製薬企業が協力して、認知度、研究資金、治療へのアクセスを向上させる必要があります。

主な市場促進要因

ヘルパンギーナの高い有病率

主な市場課題

不十分な診断ツール

主要市場動向

抗ウイルス療法の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のヘルパンギーナ治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療法別（局所麻酔薬、イブプロフェンまたはアセトアミノフェン、その他の治療）
  • ウイルス別（コクサッキーウイルスA、コクサッキーウイルスB、エンテロウイルス71、エコーウイルス）
  • エンドユーザー別（病院、在宅ケア、専門クリニック、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療法別
  • ウイルス別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域のヘルパンギーナ治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療法別
  • ウイルス別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のヘルパンギーナ治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のヘルパンギーナ治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のヘルパンギーナ治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのヘルパンギーナ治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のヘルパンギーナ治療市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Gilead Sciences Inc
• Johnson and Johnsons
• Merck & Co. Inc
• Pfizer Inc.
• AbbVie Inc.
• Vertex Pharmaceuticals Incorporated
• Sanofi S.A
• Novartis AG
• Mitsubishi Tanabe Pharma Corporation
• F. Hoffmann-La Roche Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Herpangina Treatment Market was valued at USD 1.89 Billion in 2024 and is expected to reach USD 2.86 Billion in the forecast period with a CAGR of 7.14% through 2030. The Global Herpangina Treatment Market is witnessing steady growth due to the increasing prevalence of viral infections, particularly among children. Herpangina, caused by enteroviruses such as Coxsackievirus A, leads to painful ulcers in the throat and fever, requiring symptomatic management through pain relievers, antipyretics, and hydration therapy. The rising incidence of herpangina, coupled with growing parental awareness about viral infections, is fueling demand for effective treatment options. Healthcare providers are emphasizing early diagnosis and appropriate supportive care, contributing to market expansion. The availability of over-the-counter pain relief medications and advancements in pediatric healthcare facilities further support market growth, ensuring timely management of symptoms in affected individuals.

The increasing adoption of telemedicine and digital healthcare solutions has significantly enhanced access to pediatric consultations, allowing for prompt diagnosis and management of herpangina cases. Continuous research in antiviral therapies and the development of targeted treatment approaches are expected to revolutionize the market. The rising focus on preventive healthcare, including vaccination research for enterovirus-related infections, presents a potential growth avenue. Pharmaceutical companies are actively investing in pediatric drug formulations, ensuring safe and effective treatment solutions tailored to young patients. The expansion of healthcare infrastructure and rising healthcare expenditure are driving higher accessibility to medical services, particularly in emerging economies.

Limited awareness about herpangina symptoms and treatment options in underdeveloped regions remains a major challenge. The absence of specific antiviral drugs for herpangina leads to reliance on symptomatic care, limiting treatment advancements. Concerns regarding self-medication and improper use of pain relief medications further hinder effective disease management. Stringent regulatory requirements for pediatric drug approvals add complexities to the development and commercialization of novel treatment solutions. The market also faces challenges related to seasonal outbreaks, which create fluctuations in demand, making it difficult for healthcare systems to maintain consistent preparedness. Addressing these challenges requires collaborative efforts among healthcare organizations, governments, and pharmaceutical companies to improve awareness, research funding, and treatment accessibility.

Key Market Drivers

High Prevalence of Herpangina

The high prevalence of herpangina is a compelling driver behind the robust growth of the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children, is characterized by painful throat sores, fever, and discomfort, making effective treatment imperative. The contagious nature of this illness ensures a consistent and sizable patient pool seeking medical attention, thereby fostering a constant demand for treatment options.

Children, especially those in school and daycare settings, are particularly susceptible to herpangina due to its ease of transmission through close contact. As a result, healthcare providers often encounter cases of herpangina, further underscoring the importance of developing effective treatments. The global prevalence of herpangina ensures that pharmaceutical companies and medical device manufacturers remain highly motivated to invest in research, development, and innovation in this niche healthcare sector.

Additionally, medical device manufacturers contribute to the market by developing diagnostic tools and equipment that aid healthcare professionals in the rapid and accurate identification of herpangina-causing viruses. These tools facilitate early intervention and prompt treatment, particularly in crowded and high-risk environments such as schools and daycare centers.

While specific recent statistics on herpangina prevalence are limited, data on related enteroviral infections provide insight into the disease's impact. For instance, during a 1998 outbreak in Taiwan, a total of 129,106 cases of hand, foot, and mouth disease (HFMD) and herpangina were reported. This highlights the substantial burden such viral infections can impose on healthcare systems. Given the cyclical nature of enteroviral outbreaks, similar patterns may be observed in subsequent years, underscoring the ongoing need for effective herpangina treatments. In summary, the persistent and widespread occurrence of herpangina, especially among children in communal settings, drives continuous demand for effective treatments. This demand propels pharmaceutical and medical device companies to innovate and develop targeted therapies and diagnostic tools, thereby contributing to the growth of the Global Herpangina Treatment Market.

Key Market Challenges

Inadequate Diagnostic Tools

The Global Herpangina Treatment Market, dedicated to addressing the medical needs of individuals suffering from the viral infection herpangina, faces a significant hurdle in the form of inadequate diagnostic tools. Herpangina is a contagious illness primarily affecting children and is characterized by painful throat sores, fever, and discomfort. Timely and accurate diagnosis is essential for effective treatment and containment of the disease, but the current diagnostic landscape presents challenges that hinder the market's progress.

One of the primary challenges in the herpangina treatment market is the absence of rapid and reliable diagnostic tools for identifying the viruses responsible for herpangina, notably the Coxsackievirus. Unlike some other infectious diseases with readily available diagnostic tests, herpangina lacks specific point-of-care diagnostic options. As a result, healthcare professionals often face delays in confirming a herpangina diagnosis, leading to potential misdiagnosis or the spread of the virus in high-risk environments like schools and daycare centers.

The limited availability of diagnostic tools can exacerbate the challenges associated with herpangina treatment. Without a rapid and definitive diagnosis, healthcare providers may resort to empiric treatments that focus on symptom management rather than targeting the underlying viral infection. This approach not only increases the risk of incorrect treatments but also delays the initiation of antiviral therapies, if applicable.

Moreover, inadequate diagnostic tools can hinder the ability to isolate infected individuals promptly, which is crucial in containing outbreaks, especially in settings where herpangina can easily spread among children. Without efficient diagnostic tests, identifying and isolating cases becomes a manual and time-consuming process, potentially allowing the virus to spread further.

Key Market Trends

Advancements in Antiviral Therapies

Advancements in antiviral therapies are playing a pivotal role in boosting the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children and characterized by painful throat sores, fever, and general discomfort, has long presented a challenge to healthcare providers due to its contagious nature and the lack of specific treatment options. However, recent strides in antiviral therapies are transforming the landscape of herpangina treatment.

Pharmaceutical companies are dedicating significant resources to research and develop novel antiviral drugs tailored specifically for herpangina-causing viruses, notably the Coxsackievirus. These advancements aim to address the root cause of herpangina by inhibiting the replication and spread of the virus within the body. By targeting the viral infection directly, these antiviral drugs not only alleviate the symptoms but also reduce the duration of the illness.

One of the significant advantages of these advanced antiviral therapies is their potential to combat drug-resistant strains of the virus. Over time, viruses like Coxsackievirus can adapt and become resistant to existing medications, rendering them less effective. The development of new antiviral compounds with diverse mechanisms of action helps mitigate the risk of resistance, ensuring that patients receive treatment that remains efficacious.

Additionally, these advancements in antiviral therapies contribute to enhancing the overall quality of care for individuals affected by herpangina. By shortening the duration of the illness and reducing the severity of symptoms, patients experience quicker relief and a more comfortable recovery process. This not only improves their well-being but also reduces the burden on healthcare systems by minimizing hospitalizations and outpatient visits.

Furthermore, these innovative antiviral therapies provide healthcare professionals with more effective tools for managing herpangina cases. They can confidently prescribe targeted antiviral medications that address the underlying viral infection, offering patients a more tailored and comprehensive treatment approach.

Key Market Players

• Gilead Sciences Inc
• Johnson and Johnsons
• Merck & Co. Inc
• Pfizer Inc.
• AbbVie Inc.
• Vertex Pharmaceuticals Incorporated
• Sanofi S.A
• Novartis AG
• Mitsubishi Tanabe Pharma Corporation
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Herpangina Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpangina Treatment Market, By Treatment:

• Topical Anesthetics
• Ibuprofen or Acetaminophen
• Other Treatments

Herpangina Treatment Market, By Virus:

• Coxsackie Virus A
• Coxsackie Virus B
• Enterovirus 71
• Echovirus

Herpangina Treatment Market, By End User:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Herpangina Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpangina Treatment Market.

Available Customizations:

Global Herpangina Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Herpangina Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Other Treatments)
  • 4.2.2. By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus)
  • 4.2.3. By End User (Hospitals, Homecare, Specialty Clinics, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Virus
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Herpangina Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Virus
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Herpangina Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Virus
      • 5.3.1.2.3. By End User
  • 5.3.2. India Herpangina Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Virus
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Herpangina Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Virus
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Herpangina Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Virus
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Herpangina Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Virus
      • 5.3.5.2.3. By End User

6. Europe Herpangina Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Virus
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Herpangina Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Virus
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Herpangina Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Virus
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Herpangina Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Virus
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Herpangina Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Virus
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Herpangina Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Virus
      • 6.3.5.2.3. By End User

7. North America Herpangina Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Virus
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Herpangina Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Virus
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Herpangina Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Virus
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Herpangina Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Virus
      • 7.3.3.2.3. By End User

8. South America Herpangina Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Virus
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Herpangina Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Virus
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Herpangina Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Virus
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Herpangina Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Virus
      • 8.3.3.2.3. By End User

9. Middle East and Africa Herpangina Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Virus
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Herpangina Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Virus
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Herpangina Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Virus
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Herpangina Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Virus
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Herpangina Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Gilead Sciences Inc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Johnson and Johnsons
• 14.3. Merck & Co. Inc
• 14.4. Pfizer Inc.
• 14.5. AbbVie Inc.
• 14.6. Vertex Pharmaceuticals Incorporated
• 14.7. Sanofi S.A
• 14.8. Novartis AG
• 14.9. Mitsubishi Tanabe Pharma Corporation
• 14.10. F. Hoffmann-La Roche Ltd

15. Strategic Recommendations

16. About Us & Disclaimer